HIV Prevalence and Incidence
United States, 1980 - 2010

Number of people living with HIV has grown because incidence is relatively stable and survival has increased

Hall HI et al. JAMA. 2008 Aug 6;300(5):520-9
Health Inequity

- African Americans are 8 times more likely and Latinos are 3 times more likely to have HIV than whites.
- Inequities in lifetime risk for HIV diagnosis among women:
  - 1 in 139 for all women
  - 1 in 32 African American women
  - 1 in 106 Latino women
  - 1 in 182 Native Hawaiian/Pacific Islander women
  - 1 in 217 American Indian/Alaska Native women
  - 1 in 526 white or Asian women

- HIV prevalence is associated with population density, region of residence, poverty, education, employment, and homelessness.
- Men who have sex with men (MSM) are >40 times more likely to have HIV than other men.

CDC, HIV Surveillance Report, 2009; www.cdc.gov/hiv/surveillance/resources/reports
Purcell, National STD Prevention Conference, 2010
Denning, International AIDS Society, 2010
Lifetime Risk of HIV Infection among MSM

If current trends continue, half of today’s young black MSM will have HIV by age 35

Half of all MSM will have HIV by age 50

Stall R et al. AIDS Behav. 2009 Aug;13(4):615-29
MSM, Men who have sex with men
Faster Action Now
Saves Lives and Resources Later

Stable Incidence: 550,000 additional cases in 10 years
Reducing incidence by 25%
- In 10 years would save 62,000 infections and $23 billion
- In 5 years would prevent 109,000 infections and $42 billion

Adapted from:
<table>
<thead>
<tr>
<th>Prevention with HIV(+) Persons</th>
<th>Prevention with HIV (-) Persons</th>
</tr>
</thead>
<tbody>
<tr>
<td>✓ HIV testing, linkage to care and prevention services</td>
<td>✓ Condom distribution</td>
</tr>
<tr>
<td>✓ Antiretroviral therapy</td>
<td>✓ Behavioral risk reduction interventions and condoms</td>
</tr>
<tr>
<td>✓ Retention in care and adherence</td>
<td>✓ Pre-exposure prophylaxis (PrEP)</td>
</tr>
<tr>
<td>✓ Partner services</td>
<td>✓ Post-exposure prophylaxis</td>
</tr>
<tr>
<td>✓ Behavioral risk reduction interventions and condoms</td>
<td>✓ Syringe services</td>
</tr>
<tr>
<td>✓ STD screening and treatment</td>
<td>✓ Male circumcision</td>
</tr>
<tr>
<td>✓ Perinatal transmission interventions</td>
<td>✓ Microbicides</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Prevention Not Focused on HIV Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>✓ Social mobilization</td>
</tr>
<tr>
<td>✓ Condom availability</td>
</tr>
<tr>
<td>✓ Substance use, mental health, and social support</td>
</tr>
</tbody>
</table>

Not all interventions are supported financially by CDC or other federal agencies
How Can We Reach Prevention Goals?
Combination Prevention
Multiple Disciplines and Approaches

Combining interventions is not enough

Not all interventions are effective

All effective interventions are not equal

HIV prevention

Biomedical interventions

HIV testing and linkage to care

Individual and small group interventions

Community interventions

Structural interventions

Adapted from:
**Potential interventions**

- Assess efficacy and effectiveness
- Establish cost and cost effectiveness per infections averted and life-years saved
- Determine feasibility of full-scale implementation

**HIGH-IMPACT PREVENTION (HIP)**

- Prioritize interventions
- Implement and evaluate programs
- Develop epidemic models to project impact of interventions
High-Impact Prevention (HIP)
Clinical Medicine and Public Health

- All persons with HIV
- All diagnosed persons
- Any HIV care
- Regular HIV care
- Prescribed ART

PUBLIC HEALTH

CLINICAL MEDICINE

MMWR 2011 Dec 2;60(47):1618-23
ART, Antiretroviral therapy
Viral Load Suppression

Suppressed viral load
25%

All persons with HIV
All diagnosed persons
Any HIV care
Regular HIV care
Prescribed ART

Hall I, XIX International AIDS Conference, 2012
ART, Antiretroviral therapy
Public health responsibility to close gaps in HIV care and prevention services

- At individual level, lower viral load reduces morbidity and mortality, and reduces chance of spreading HIV
- Population level, viral load leads to fewer new infections

Emulate successful programs in other disease areas

- Example: Hemoglobin A1C registry and diabetes monitoring in New York City
Success in San Francisco
Community Viral Load and HIV Incidence

CVL, Community viral load
$339 million annually, allocated based on HIV prevalence
- Allows flexibility based on local epidemic modeling and needs
- Focuses on interventions that will have greatest impact on epidemic with 75% of budget focused on 4 key strategies: HIV testing, prevention with positives including ART, policy, and condom distribution

Matching Prevention Funds to the Epidemic

When CDC’s new approach is fully implemented, HIV prevention resources will closely match the geographic burden of HIV.


Proportion of CDC Core HIV Prevention Funding—FY2016

1 Maps do not include U.S. territories receiving CDC HIV prevention funding.
2 New funding allocation methodology will be fully implemented by FY2016; this breakdown assumes level overall funding.
Expanded Testing Initiative
- 2.8 million tests conducted in first 3 years
- 18,000 people newly diagnosed with HIV
  - 70% African American and 12% Latino
- Averted an estimated 3,400 HIV infections
- Achieved a return of $1.97 for every dollar invested

Care and Prevention demonstration projects
- $14.5 million annually over 3 years for 6 - 9 states
- Monitor and improve diagnosis, linkage, retention, ART provision, viral suppression, and behavioral prevention by using individual and community-level surveillance data
- Provide information to patients and clinicians to improve outcomes
Conclusions

- Growing number of people with HIV and restricted budget require higher impact strategies
- Window for success may be closing, requiring swift action
- Large disparities require conscious application of health equity approaches
- Public health prevention, care, and surveillance programs must be integrated
HIV Surveillance In Action

Irene Hall, PhD, MPH, FACE
Division of HIV/AIDS Prevention
Centers for Disease Control and Prevention
HIV Case Surveillance
Data for Prevention

- **Sources of reports**
  - Hospital practitioners
  - Private practitioners
  - Public clinics
  - Laboratories

- **Surveillance then**
  - Few sentinel events

- **Surveillance now**
  - Continuous data collection
National HIV/AIDS Strategy
Primary Goals

- Reduce the number of people who become infected with HIV
- Increase access to care and optimize health outcomes for people living with HIV
- Reduce HIV-related health disparities

www.whitehouse.gov/sites/default/files/uploads/NHAS.pdf
National HIV/AIDS Strategy
Indicators of Need and Outcome for Prevention Efforts

- Incidence
- Prevalence, including undiagnosed persons
  - Persons unaware of their infection disproportionately transmit HIV
  - Identifying them for targeted testing: first step in prevention efforts
- Transmission rate
  - Annual number of new infections per 100 persons living with HIV
- Linkage to care
- Retention in care
- Viral suppression
HIV Surveillance: Incidence

- First incidence estimates released in 2008
- First 4-year trend released in 2011
- Persons diagnosed with HIV may have been infected for many years
- Laboratory assays can distinguish recent from long-term infections at the population level
- Incidence estimates are based on the number of recent infections and additional information on testing among persons diagnosed with HIV
Estimated HIV Incidence Rates, by Race/Ethnicity
United States, 2009

Annual U.S. incidence: ~ 50,000 cases
2009 U.S. incidence rate: 9.0/100,000

- Asian: 8
- White: 9
- American Indian/Alaska Native: 14
- Multiple races: 18
- Hispanic/Latino: 26
- Native Hawaiian/Other Pacific Islander: 44
- Black/African American: 70

Rate per 100,000

Prejean, J et al. PLoS ONE 6(8): e17502
HIV Infection Diagnosis Rates Among Adults and Adolescents, 2010

Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. All displayed data have been statistically adjusted to account for reporting delays, but not for incomplete reporting.
Adults and Adolescents Living with HIV Infection and HIV Transmission Rate, United States

No. living with undiagnosed HIV infection
No. living with diagnosed HIV infection
Transmission rate

Year

Estimated number

Rate per 100 persons living with HIV

MMWR 2012;61(Suppl; June 15, 2012):57-64
Holtgrave et al. The Open AIDS Journal 2012;6:20-22
Persons with HIV Engaged in Selected Stages of the Continuum of Care, United States

<table>
<thead>
<tr>
<th>Stage of Care</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnosed</td>
<td>82</td>
</tr>
<tr>
<td>Linked to care</td>
<td>66</td>
</tr>
<tr>
<td>Retained in care</td>
<td>37</td>
</tr>
<tr>
<td>Prescribed ART</td>
<td>33</td>
</tr>
<tr>
<td>Viral Suppression</td>
<td>25</td>
</tr>
</tbody>
</table>

Hall et al. XIX International AIDS Conference, 2012
ART, Antiretroviral therapy
Aggregate data can be used on various geographic levels for

- Prevention planning
- Resource allocation
- Outcome evaluation
Individual level data help determine whether people are in care and/or have a suppressed viral load

- This information can be used
  - To alert providers to engage or re-engage people in care or
  - By the health department to contact patients directly in order to assure they receive the services they need

Maintaining personally identifiable data and these follow-up activities require careful planning

- Protocols for confidential data sharing
- Seeking input from the community and care providers
- Evaluation
Summary

- Data indicate targets for high-impact prevention
- Data allow monitoring of key outcome indicators of the National HIV/AIDS Strategy

Surveillance has become a continuous data collection system that can provide data for public health action on provider and individual level.
Modeling to Identify Optimal Allocation of HIV Prevention Resources in a City Health Department

Stephanie L Sansom, PhD, MPP, MPH
Division of HIV/AIDS Prevention
Centers for Disease Control and Prevention
The Value of Modeling

- Modeling of resource allocation helps state and local health departments
  - Divide scarce prevention dollars among programs and population
  - Achieve the most impact at least cost
  - Identify high-impact prevention strategies
- Model optimal combination of HIV prevention programs to address city’s HIV epidemic
- Develop a tool other local jurisdictions might use
HIV resource allocation model

- Projects new HIV cases for 1--5 years
- Estimates best allocation of HIV prevention budget
  - Among programs and populations
  - To prevent most HIV cases
- Incorporates
  - HIV prevention budget: $12 million
  - Size and characteristics of populations with or at risk for HIV
  - Percent of risk population reachable
  - Prevention intervention characteristics
    - Cost, efficacy, and duration of effect
Methods

- **Calculate reduced likelihood of HIV infection following prevention intervention**
  - Number of and type of HIV exposures
    - Unprotected sex and needle sharing
  - HIV prevalence among partners
  - HIV transmission probability per exposure
  - Efficacy of intervention in preventing HIV

- **Calculate cost of intervention per infection averted**
  - Cost of providing intervention divided by reduced likelihood of infection
Methods

- **CDC criteria: Inclusion of interventions that are**
  - Aligned with principles of high-impact HIV prevention
  - Required in CDC-funded cities with high HIV prevalence
  - Targeted to populations with greatest number of new infections
  - Supported by scientific evidence on infection rate reduction
### Prevention with HIV(+) Persons

- HIV testing, linkage to care and prevention services
- Antiretroviral therapy
- Retention in care and adherence
- Partner services
- Behavioral risk reduction interventions and condoms
- STD screening and treatment
- Perinatal transmission interventions

### Prevention with HIV (-) Persons

- Condom distribution
- Behavioral risk reduction interventions and condoms
- Pre-exposure prophylaxis (PrEP)
- Post-exposure prophylaxis
- Syringe services
- Male circumcision
- Microbicides
- STD screening and treatment

### Prevention Not Focused on HIV Status

- Social mobilization
- Condom availability
- Substance use, mental health, and social support

Not all interventions are supported financially by CDC or other federal agencies
**Philadelphia HIV Community Profile**

<table>
<thead>
<tr>
<th>Risk group</th>
<th>New diagnosis* Number (%)</th>
<th>PLWH population size&amp; Number (%)</th>
<th>At-risk population size# Number (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>High-risk heterosexuals</td>
<td>340 (37)</td>
<td>8,528 (35)</td>
<td>245,208 (76)</td>
</tr>
<tr>
<td>Intravenous drug users</td>
<td>136 (15)</td>
<td>7,175 (30)</td>
<td>41,001 (13)</td>
</tr>
<tr>
<td>Men who have sex with men</td>
<td>433 (48)</td>
<td>8,356 (35)</td>
<td>37,882 (12)</td>
</tr>
<tr>
<td>Total</td>
<td>909 (100)</td>
<td>24,060 (100)</td>
<td>324,091 (100)</td>
</tr>
</tbody>
</table>

* New HIV diagnoses in Philadelphia in 2009

& PLWH, People living with HIV, undiagnosed and diagnosed in Philadelphia in 2009

# Estimated number of people at high risk of HIV infection in each risk category
## Cost per Infection Averted ($)

<table>
<thead>
<tr>
<th>Untargeted interventions</th>
<th>Cost per new infection averted (rank)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testing in clinical settings</td>
<td>51,293 (3)</td>
</tr>
<tr>
<td>Partner services</td>
<td>99,105 (7)</td>
</tr>
<tr>
<td>Linkage to care</td>
<td>114,644 (8)</td>
</tr>
<tr>
<td>Retention in care</td>
<td>75,665 (5)</td>
</tr>
<tr>
<td>Adherence to ART</td>
<td>42,753 (2)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Targeted interventions</th>
<th>HRH</th>
<th>IDU</th>
<th>MSM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testing in non-clinical settings</td>
<td>866,272 (12)</td>
<td>53,935 (4)</td>
<td>17,965 (1)</td>
</tr>
<tr>
<td>Behavioral intervention for HIV+ people</td>
<td>594,796 (10)</td>
<td>700,005 (11)</td>
<td>97,410 (6)</td>
</tr>
<tr>
<td>Behavioral intervention for HIV- people</td>
<td>15,642,127 (14)</td>
<td>2,931,406 (13)</td>
<td>327,210 (9)</td>
</tr>
</tbody>
</table>

ART, Antiretroviral therapy  
HRH, High risk heterosexuals  
IDU, Injection drug users  
MSM, Men who have sex with men
# Optimal Allocation: $12 Million Budget

<table>
<thead>
<tr>
<th>Untargeted interventions</th>
<th>Budget (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testing in clinical settings</td>
<td>39</td>
</tr>
<tr>
<td>Partner services</td>
<td></td>
</tr>
<tr>
<td>Linkage to care</td>
<td></td>
</tr>
<tr>
<td>Retention in care</td>
<td>32</td>
</tr>
<tr>
<td>Adherence to ART</td>
<td>7</td>
</tr>
</tbody>
</table>

### Targeted interventions

<table>
<thead>
<tr>
<th>HRH</th>
<th>IDU</th>
<th>MSM</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>13</td>
<td>8</td>
</tr>
</tbody>
</table>

| Testing in non-clinical settings             | 13          |
| Behavioral intervention for HIV+ people     |             |
| Behavioral intervention for HIV- people     |             |

### Total

<table>
<thead>
<tr>
<th>ART, Anti retroviral therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>HRH, High risk heterosexuals</td>
</tr>
<tr>
<td>IDU, Injection drug users</td>
</tr>
<tr>
<td>MSM, Men who have sex with men</td>
</tr>
</tbody>
</table>
### Optimal Allocation: $25 Million Budget

<table>
<thead>
<tr>
<th>Untargeted interventions</th>
<th>Budget (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testing in clinical settings</td>
<td>19</td>
</tr>
<tr>
<td>Partner services</td>
<td>19</td>
</tr>
<tr>
<td>Linkage to care</td>
<td>16</td>
</tr>
<tr>
<td>Retention in care</td>
<td>32</td>
</tr>
<tr>
<td>Adherence to ART</td>
<td>3</td>
</tr>
</tbody>
</table>

### Targeted interventions

<table>
<thead>
<tr>
<th></th>
<th>HRH</th>
<th>IDU</th>
<th>MSM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testing in non-clinical settings</td>
<td>6</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Behavioral intervention for HIV+ people</td>
<td>2</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Behavioral intervention for HIV- people</td>
<td></td>
<td></td>
<td>11</td>
</tr>
</tbody>
</table>

**Total**

ART, Anti retroviral therapy  
HRH, High risk heterosexuals  
IDU, Injection drug users  
MSM, Men who have sex with men
# Optimal Allocation: $50 Million Budget

<table>
<thead>
<tr>
<th>Untargeted interventions</th>
<th>Budget (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testing in clinical settings</td>
<td>10</td>
</tr>
<tr>
<td>Partner services</td>
<td>9</td>
</tr>
<tr>
<td>Linkage to care</td>
<td>8</td>
</tr>
<tr>
<td>Retention in care</td>
<td>9</td>
</tr>
<tr>
<td>Adherence to ART</td>
<td>2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Targeted interventions</th>
<th>HRH</th>
<th>IDU</th>
<th>MSM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testing in non-clinical settings</td>
<td>16</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Behavioral intervention for HIV+ people</td>
<td>2</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Behavioral intervention for HIV- people</td>
<td>7</td>
<td>6</td>
<td>5</td>
</tr>
</tbody>
</table>

**Total**

ART, Anti retroviral therapy
HRH, High risk heterosexuals
IDU, Injection drug users
MSM, Men who have sex with men
Philadelphia has used CDC model to inform funding decisions

- More screening of MSM in non-clinical settings
- More behavior change programs for positives, especially MSM
- Fewer behavior change programs for negatives, none for heterosexuals

MSM, Men who have sex with men
Limitations of Modeling

- **Models often rely on uncertain data and assumptions**
  - Critical to conduct sensitivity analyses
  - Validate projected outcomes against empirical data

- **Models may not incorporate important elements**
  - Equity
  - Political or practical barriers to implementation
  - Synergies among prevention interventions
Advantages of Modeling

- Modeling can
  - Synthesize data from many sources (including local data)
  - Summarize complex issues in a transparent way
  - Serve as a methodology for comparing interventions
  - Illuminate planning and programmatic decisions

- CDC continues to refine models to help support planning of local HIV prevention
Overview of the National HIV/AIDS Strategy Implementation

Grant Colfax, MD
Office of National AIDS Policy
The White House
National HIV/AIDS Strategy
2015 Health Targets

- Reducing new infections
  - Lower annual number of new infections by 25%
  - Reduce transmission rate by 30%
  - Increase from 79% to 90% the percentage of people living with HIV who know their status

- Increasing access to care and improving health outcomes
  - Increase the proportion of newly diagnosed patients linked to care within 3 months of diagnosis from 65% to 85%
  - Increase proportion of Ryan White clients who are engaged in care from 73% to 80%
  - Increase number of Ryan White clients with permanent housing from 82% to 86%
Reducing HIV-related health disparities and health inequities

- Increase the proportion of diagnosed gay and bisexual men with undetectable viral load by 20%
- Increase the proportion of Black Americans with undetectable viral load by 20%
- Increase the proportion of Latinos with undetectable viral load by 20%
President Obama’s 2013 HIV Budget

- $22.3 billion for domestic HIV-related activities
- $963 million increase over 2012
- $1 billion for AIDS Drug Assistance Programs
Reaching NHAS Goals

- **Prioritize health outcomes**
  - A few key metrics

- **Smarter investments**
  - Target populations
  - Evidence-based interventions

- **Shared responsibility**
  - Federal, State, local, non-profit and corporate partners

- **Accountability**
  - Scale up what’s working
  - Change what’s not
  - Emphasize effectiveness and cost savings
Aligning Resources with the Epidemic

Matching Prevention Funds to the Epidemic¹

When CDC’s new approach is fully implemented, HIV prevention resources will closely match the geographic burden of HIV.

Proportion of Americans Living with an HIV Diagnosis (2008)

Proportion of CDC Core HIV Prevention Funding—FY2016²

¹Maps do not include U.S. territories receiving CDC HIV prevention funding.

²New funding allocation methodology will be fully implemented by FY2016; this breakdown assumes level overall funding.

www.cdc.gov/hiv/strategy/hihp/healthDepartments/
Optimal combination of interventions?
Metrics to measure local program success?
Resources used by populations at greatest risk?
Are interventions evidence-based, scalable, sustainable, and effective?

CDC’s High-Impact Prevention: Ground Level Implementation of NHAS

NHAS, National HIV/AIDS Strategy
HIV Treatment: a Win-Win-Win

- Earlier treatment improves health: HHS and IAS guidelines now recommend starting treatment regardless of immune status
- Treatment is prevention: reduction in transmission risk to partners 96%
- Treatment is cost effective

Increasing HIV Testing and Treatment to Achieve the Strategy’s Goals

NHAS, National HIV/AIDS Strategy
HIV and Health Coverage

Of U.S. PLWHA, approximately:

- 13% have private coverage
- 24% have no coverage
- 47% receive Medicaid
- Over 500,000 receive some form of Ryan White services

Rates of Persons Living with an HIV Diagnosis & Percent of Population without Health Insurance, by County, 2009

Kaiser Family Foundation; aidsvu.org
PLWHA, Persons living with HIV/AIDS
HIV-related Disparities and Healthcare

HIV health outcome disparities in:

- Time To AIDS and death after AIDS diagnosis, for black and Latino MSM relative to white MSM
- Excess deaths, for blacks compared to whites
- Life expectancy losses, for Latinos compared to blacks or whites
- Life expectancy losses, for Latina and black women compared to white women

BUT: No difference in time to AIDS or mortality by race in HMO system

Silverberg et al, J Gen Intern Med. 2009 July 16;24(9): 1066-72
HMO, Health Maintenance Organization
Toward Health Equity: The Affordable Care Act

- **Expands coverage to 30 million Americans**
  - Tens of thousands with HIV
  - Millions of blacks and Latinos

- **Prohibits denials of coverage based on HIV status**

- **Already:**
  - Millions have increased prevention service coverage
  - Millions of young adults covered on parents’ plans

- **Coverage necessary but not sufficient to improve HIV outcomes**
  - Continued need to address stigma, discrimination, and barriers to access and engagement in care

Office of the Assistant Secretary for Planning and Evaluation, 2012
Measuring HIV-related Outcomes: Towards a National Consensus

- Parsimony
- Harmony
- Achievability
- Sustainability
- Usability
- Shareability

Ongoing NHAS Implementation Needs

- Continued collaboration among Federal, State, local government, and private partners
- Flexibility at local level while maintaining alignment with NHAS principles
- Technical assistance to prepare HIV workforce for ongoing changes in environment
- Shift from process-oriented to outcome-oriented metrics
- Prioritize maximizing the continuum of care
- Research to determine best ways to move forward among multiple options
- Support ongoing basic and clinical research
Vision for the National HIV/AIDS Strategy

“The United States will become a place where new HIV infections are rare and when they do occur, every person, regardless of age, gender, race/ethnicity, sexual orientation, gender identity or socio-economic circumstance, will have unfettered access to high quality, life-extending care, free from stigma and discrimination”
Acknowledgements

HHS: Howard Koh, Ron Valdiserri, Andrew Forsyth, Greg Millett
ONAP team: James Albino, Aaron Lopata, Helen Pajcic

Grant Nash Colfax, MD
Director
Office of National AIDS Policy
Domestic Policy Council
The White House

Email: Grant_N_Colfax@who.eop.gov
Science of Optimizing HIV Prevention
Jonathan Mermin, MD, MPH, Director, Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention

HIV Surveillance in Action
Irene Hall, PhD, MPH, FACE, Chief, HIV Incidence and Case Surveillance Branch, Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention

Modeling to Identify Optimal Allocation of HIV Prevention Resources in a City Health Department
Stephanie Sansom, PhD, MPP, MPH
Quantitative Sciences and Data Management Branch, Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention

National HIV/AIDS Strategy Implementation Update
Grant Colfax, MD, Director, Office of National AIDS Policy, The White House